and have for the discovery, development and commercialisation of small molecules that modulate new G protein-coupled receptor (GPCR) targets linked to diabetes and metabolic diseases.
This alliance will utilise Sosei鈥檚 StaR technology and structure-based drug design (SBDD) platform along with wide-ranging drug development and marketing capabilities and therapeutic area abilities of Lilly in these disease areas.
According to the deal, Sosei will work on a variety of GPCR targets suggested by Lilly to offer new target-selective small molecule hit candidates for advanced development and marketing.
On signing the agreement, Lilly will make $37m in upfront payment to Sosei Heptares, which is also entitled to get up to $694m on meeting development and commercial milestones.
Additionally, Sosei Heptares will receive tiered royalty payments on product sales worldwide.
Sosei Heptares UK Research & Development head Matt Barnes said: 鈥淭his new agreement with Lilly further reinforces our position as a global partner of choice for GPCR-focused drug discovery targeting major diseases where patients remain in need of new and effective therapies.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData鈥淟illy is a recognised world leader in diabetes and metabolic diseases, and we look forward to a collaboration that brings together our respective and complementary expertise with the goal of identifying and developing novel candidates to advance in these important areas of unmet need.鈥�
In October,聽Lilly entered a definitive agreement to acquire Akouos聽in a deal valued at up to nearly $610m in cash.
Akouos focuses on developing adeno-associated viral gene therapies for treating inner ear conditions, including sensorineural hearing loss.
